Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.

OBJECTIVE To evaluate the detection of near-infrared fluorescence from prostate tumors stained with a prostate-specific membrane antigen (PSMA)-targeted tracer developed in our institution with a novel robotic imaging system. METHODS Prostate cancer cell lines PC3-pip (PSMA positive) and PC3-flu (PSMA negative) were implanted subcutaneously into 6 immunodeficient mice. When tumors reached 5 mm, a PSMA-targeted fluorescent conjugate was injected intravenously. The first 3 mice underwent near-infrared imaging immediately and hourly up to 4 hours after injection to determine the time necessary to obtain peak fluorescence and were killed. The last 3 mice were imaged once preoperatively and were euthanized 120 minutes later. Excision of the tumors was performed by using a novel robotic imaging system to detect near-infrared fluorescence in real time. Specimens were submitted for pathology. RESULTS In the first 3 mice, we found 120 minutes as the time needed to observe peak fluorescence from the PSMA-positive tumors. We identified discrete near-infrared fluorescence from 2 of 3 PSMA-positive tumors with the robotic imaging system. Surgical margins were negative for all excised specimens except for one PSMA-negative tumor. CONCLUSIONS Real-time near-infrared fluorescence imaging of prostate cancer is feasible with a novel robotic imaging system. Further research is needed to optimize the signal intensity detectable from prostate cancer with our tracer. Toxicologic studies are needed before its clinical use.

[1]  Tessa Buckle,et al.  Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. , 2011, European urology.

[2]  Hisataka Kobayashi,et al.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. , 2011, Bioconjugate chemistry.

[3]  Zhenghong Lee,et al.  Targeted treatment of prostate cancer , 2007, Journal of cellular biochemistry.

[4]  Simon A. Williams,et al.  Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human , 2006, The Prostate.

[5]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[6]  Alexander L. Vahrmeijer,et al.  Optical Image-guided Surgery—Where Do We Stand? , 2010, Molecular Imaging and Biology.

[7]  Tiancheng Liu,et al.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Hani Rashid,et al.  Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. , 2011, The Journal of urology.

[9]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[10]  J. Neale,et al.  Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). , 2001, Journal of medicinal chemistry.

[11]  Eva M. Sevick-Muraca,et al.  Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats , 2010, Molecular Imaging and Biology.

[12]  D. M. Olive,et al.  A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. , 2007, Analytical biochemistry.